PENNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Penumbra Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$322.41+1.55 (+0.48%)
Close on Oct 19, 2026
- Market cap
- $12.76B
- P/E (TTM)
- 79.2
- Dividend yield
- –
Penumbra Inc revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombectomy | $1.00B | $975.29M | $947.92M | $913.35M | $881.07M | $854.32M | $815.48M | $786.13M | $761.07M | $720.07M | $677.34M | – | 66.7% | +14.0% |
| Vascular | – | – | – | – | – | – | – | – | – | – | – | $638.26M | – | – |
| Neuro | – | – | – | – | – | – | – | – | – | – | – | $470.31M | – | – |
By region
From the segment and revenue-disaggregation notes of Penumbra's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.